TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05822765
Drug: Epinephrine concentration of 1:1000000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Study: NCT05822765
Drug: Epinephrine concentration of 1:500000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Study: NCT06652139
Drug: BEAM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
Study: NCT00465322
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05466201
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive transfusion of blood products, including platelets and red blood cells.
Study: NCT05533229
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
Study: NCT05901389
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Study: NCT05908643
Drug: pTTL
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
Study: NCT03917407
Drug: DUR-928 (Moderate AH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.
Study: NCT03917407
Drug: DUR-928 (Severe AH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study.
Study: NCT05974059
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
Study: NCT05292339
Drug: Ketorolac injection to the shoulder, elbow, wrist, or hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
Study: NCT05542173
Drug: BALI association
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
Study: NCT05542173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
Study: NCT05323058
Drug: tulsi extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% topical oral spray
Study: NCT00000659
Drug: CD4 Antigens
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05637060
Drug: Test Drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study: NCT05637060
Drug: Reference Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study: NCT06326983
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
Study: NCT06326983
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
Study: NCT05654077
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study: NCT06533761
Drug: Eganelisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: eganelisib will be administered as monotherapy
Study: NCT05792735
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
Study: NCT04637282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste and color-matched drug-free solution
Study: NCT06439277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06008015
Drug: BR1015
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06008015
Drug: BR1015-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06008015
Drug: BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05991622
Drug: Combined LAI Treatment: Cabenuva and Sublocade
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
Study: NCT06523400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT04959175
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
Study: NCT06572228
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT06572228
Drug: ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at a blinded dose
Study: NCT06566248
Drug: Placebo+NUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication.
Study: NCT04547439
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3 mg will be taken nightly for 8 weeks
Study: NCT00000724
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04404192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration of 100 microliters to each nostril 4 times a day.
Study: NCT05107128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-718-matching oral capsules.
Study: NCT06649656
Drug: TQB2252 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
Study: NCT05799248
Drug: rhPSMA-7.3 (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
Study: NCT05518318
Drug: Chemotherapy of Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
Study: NCT05303844
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: H101 intratumorally injection starts at day 0.
Study: NCT05145218
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
Study: NCT05219513
Drug: RO7443904
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
Study: NCT06475105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Study: NCT05401032
Drug: 5-hidroxitriptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication, 3 times a day for 6 months.
Study: NCT06280391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
Study: NCT05412446
Drug: ADAPT6-SPECT
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
Study: NCT04718389
Drug: Standard of care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
Study: NCT05743244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Abrocitinib or Ritlecitinib
Study: NCT06495632
Drug: Motrin and narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: See described earlier
Study: NCT06653738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily per os for 3 years
Study: NCT05783557
Drug: Cleviprex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03935451
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
Study: NCT06494111
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05664074
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg
Study: NCT05664074
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
Study: NCT06651892
Drug: Glycophos Injectable Product
Normalized name: Glycophos Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous sodium glycerophosphate as the standard of care or active control
Study: NCT05529095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill)
Study: NCT00004845
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004845
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06374043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05354453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05148195
Drug: BD0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
Study: NCT05148195
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2，Q2W
Study: NCT05050279
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT06507059
Drug: Antiretroviral Combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard all-oral antiretroviral combinations
Study: NCT05254847
Drug: Capecitabine combined with lenvatinib and tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine combined with lenvatinib and tislelizumab
Study: NCT04723303
Drug: Umbilical Cord Lining Stem Cells
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV infusion of ULSCs will be administered.
Study: NCT06472076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT04716712
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
Study: NCT04716712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching identical placebo in packaging, appearance, and taste.
Study: NCT06317064
Drug: Ibuprofen and Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days.
Study: NCT05312892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00291213
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06535230
Drug: Manual anesthesia induction
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
Study: NCT06535230
Drug: Anesthesia induction with Target controlled infusions (TCI)
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
Study: NCT00121043
Drug: Kineret® (Anakinra)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05649059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
Study: NCT04510428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
Study: NCT06540352
Drug: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
Study: NCT04945226
Drug: IVL3001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride long acting injection
Study: NCT06150664
Drug: CTX-8371
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
Study: NCT04849741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: zilganersen-matching placebo will be administered by ITB injection.
Study: NCT04899570
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
Study: NCT05804123
Drug: 0.9% NaCl physiological saline Nasal-spraying
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT06435065
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
Study: NCT06435065
Drug: THERACAL LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
Study: NCT06435065
Drug: TRISTRONTIUM ALUMINATE
Normalized name: bismuth aluminate
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
Study: NCT05098262
Drug: DA-5210 10/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05098262
Drug: DA-5210-R 10/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05870800
Drug: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
Study: NCT05870800
Drug: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Study: NCT05870800
Drug: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Study: NCT04848857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
Study: NCT04915950
Drug: Temanogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.
Study: NCT04915950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
Study: NCT04909879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient solution
Study: NCT05737030
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid combination
Study: NCT05594745
Drug: Systane Free
Normalized name: Systane Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: eyedrop
Study: NCT05352633
Drug: Standard BP Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Study: NCT05600777
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of BLU-5937 Tablets
Study: NCT05600777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study: NCT04843891
Drug: [64]Cu Macrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.